Details for New Drug Application (NDA): 086162
✉ Email this page to a colleague
NDA 086162 describes BUTALBITAL, ASPIRIN AND CAFFEINE, which is a drug marketed by Lgm Pharma, Nostrum Labs Inc, Watson Labs, Actavis Elizabeth, Fosun Pharma, Halsey, Hikma Intl Pharms, Ivax Pharms, Puracap Pharm, Quantum Pharmics, and Strides Pharma, and is included in twelve NDAs. It is available from two suppliers. Additional details are available on the BUTALBITAL, ASPIRIN AND CAFFEINE profile page.
The generic ingredient in BUTALBITAL, ASPIRIN AND CAFFEINE is aspirin; butalbital; caffeine. There are twenty-two drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the aspirin; butalbital; caffeine profile page.
The generic ingredient in BUTALBITAL, ASPIRIN AND CAFFEINE is aspirin; butalbital; caffeine. There are twenty-two drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the aspirin; butalbital; caffeine profile page.
Summary for 086162
| Tradename: | BUTALBITAL, ASPIRIN AND CAFFEINE |
| Applicant: | Hikma Intl Pharms |
| Ingredient: | aspirin; butalbital; caffeine |
| Patents: | 0 |
Profile for product number 002
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | 325MG;50MG;40MG | ||||
| Approval Date: | Feb 16, 1984 | TE: | RLD: | Yes | |||||
Complete Access Available with Subscription
